Axsome Therapeutics, Inc. 8-K

What Happened
Axsome Therapeutics, Inc. announced on June 3, 2026 that it has reached a settlement resolving all patent litigation related to SUNOSI® (solriamfetol). The company filed the announcement in an SEC Form 8‑K (Item 8.01) and included the full press release as Exhibit 99.1.

Key Details

• Filing date: June 3, 2026 (Form 8‑K, Item 8.01 - Other Events).
• Subject: Settlement resolving all SUNOSI® (solriamfetol) patent litigation.
• Disclosure: The company filed a press release titled “Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation” as Exhibit 99.1 (incorporated by reference).
• Signature: Form 8‑K signed by Herriot Tabuteau, M.D., President and Chief Executive Officer.

Why It Matters
This 8‑K reports a material legal development for Axsome — the company states the patent litigation over its sleep‑disorder drug SUNOSI has been resolved. Investors should review the press release (Exhibit 99.1) for any additional details or terms of the settlement, as the Form 8‑K itself does not provide settlement terms or financial impact.